Do Fluoroquinolones Trigger Aortic Disease? Key Steps in Conducting Impactful Research

Needs Statement

General, plastic, thoracic, vascular, cardiothoracic, abdominal transplantation and surgical oncology physicians, residents, fellows and medical students need to be regularly updated on novel therapies, as well as advances in surgical care and clinical practices that will aid them in treating a variety of surgical procedures to increase the patient care experience and improve practice efficiency.

Educational Objectives

At the conclusion of the session, the participants should be able to:

• Describe key steps to developing clinically relevant, impactful research projects.
• Discuss how these steps helped advance a project focused on determining whether fluoroquinolones promote aortic disease.
• Review the newest scientific evidence about the risks of using fluoroquinolones in patients with aortic disease and explain the latest warnings that have been released by the U.S. Food and Drug Administration and the European Medicines Agency in the European Union.

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

January 1, 2021 through January 31, 2023. Original release date: January 1, 2021.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.